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Abstract Follicular dendritic cells (FDCs) play pivotal roles in
germinal center (GC) responses in secondary lymphoid follicles,
and their functions are in£uenced by cytokines present in the
GC. We investigated the functional e¡ects of interleukin-4
(IL-4) using an established FDC-like line of HK cells. In spite
of the activation of ERK1/2 and PI3K/Akt pathways by IL-4,
which are implicated in the induction of cell proliferation and
survival, IL-4 did not exhibit protective function on anisomycin-
induced apoptosis of HK cells, but rather slightly enhanced it.
This IL-4 e¡ect correlated with the up-regulation of anisomycin-
induced p38 signaling, which is attenuated by inhibition of the
PI3K/Akt pathway. Expression of an active form of Akt in-
creased anisomycin-elicited activation of p38 and its upstream
kinase MKK3/6. Our data indicate a positive cross-talk between
the p38 and PI3K/Akt pathways.
6 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
Key words: IL-4; Akt; p38; Follicular dendritic cell
1. Introduction
The germinal center (GC) of secondary lymphoid organs
represents an anatomical site where B cells undergo somatic
mutations, isotype switching and a⁄nity selection, allowing
the generation of memory B cells and plasma cells [1]. Fol-
licular dendritic cells (FDCs) and T cells are required for
normal GC development. FDCs are found closely associated
with GC B cells. The interaction between these two cell types
involves not only Ag-speci¢c recognition but also a set of
adhesion and co-stimulatory molecules which are necessary
for GC B cells to survive and di¡erentiate into memory cells
[2]. This B cell process is also in£uenced by cytokines present
in the GC microenvironment. Among the T cell-derived cyto-
kines, interleukin-4 (IL-4) is required for the di¡erentiation of
B cells and controls the speci¢city of immunoglobulin class
switching [3]. In vitro experiments mimicking GC reaction
have indicated that IL-4 is a growth factor promoting GC B
cell proliferation [4]. Apart from the e¡ects of IL-4 on GC B
cells, IL-4 can also in£uence the function of FDC in support-
ing GC reaction. FDC in vivo is shown to express IL-4 re-
ceptors [5]. Cultured human FDC lines respond to IL-4 by
up-regulating the expression of vascular cell adhesion mole-
cule-1 (VCAM-1) and CD23 [6,7]. However, intracellular
pathways that are activated by IL-4 and that contribute to
FDC function have not been established as yet.
Signal transduction through the IL-4 receptor involves
three major pathways: JAK^STAT6, Raf^MEK^MAPK
and the phosphatidylinositol-3P-kinase (PI3K)^Akt signaling
pathways [8]. The two latter pathways are well recognized
for their contribution to cellular proliferation and survival.
Upon Ag stimulation, FDCs expand and di¡erentiate to
form web-like network structures. The FDC networks in the
secondary lymphoid follicles are stably maintained for long
periods of time until the Ag is cleared, and this maintenance
appears to be regulated by appropriate cytokines that pro-
mote cell growth and survival [9]. Thus, having hypothesized
that IL-4 is a cytokine that elicits the proliferation and sur-
vival signals for FDCs, we analyzed the intracellular signal
transduction pathways and their e¡ects by using an estab-
lished FDC line of HK cells. HK cells exhibit functional
and phenotypic characteristics of FDC in vivo, delaying apo-
ptosis and stimulating growth and di¡erentiation of GC B
cells [10]. In addition, activated T cells augmented the prolif-
eration of HK cells via contact and by soluble factor-depen-
dent means [11], which is analogous to the in vivo observation
that T cells are required for GC reaction [12] and FDC devel-
opment [13]. HK cells also responded to TNF and soluble
CD40 ligand (sCD40L) by activating ERK and p38 [14].
Here we show that IL-4 indeed acts as a growth factor for
HK cells, activating ERK and PI3K/Akt pathways. Unexpect-
edly, despite the well-established function of Akt in protecting
cells from apoptosis induced by various stimuli, including
treatment of anisomycin, a protein synthesis inhibitor that
leads to the activation of p38 [15,16], we found that IL-4-
activated Akt sensitizes the anisomycin-induced p38 signaling
pathway, which is responsible for the increased apoptosis in-
duced by anisomycin.
2. Materials and methods
2.1. Cell cultures and reagents
Cell culture media were purchased from Life Technologies (Rock-
ville, MD, USA). An established FDC line [10^13], HK cells were
grown in RPMI 1640 supplemented with 10% heat-inactivated fetal
calf serum (FCS), 2 mM glutamine, 100 U/ml penicillin and 100 Wg/ml
streptomycin. HK cells with passages 13^17 were used for various
experiments. Human IL-4 was purchased from RpD Systems (Min-
neapolis, MN, USA). Recombinant human TNF was obtained from
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Biotech Research Institute, LGCI, Korea. Anisomycin was purchased
from Sigma. PD098059, SB203580, wortmannin, LY294002 and
DMSO were purchased from Calbiochem (La Jolla, CA, USA). The
rabbit anti-phospho-ERK, anti-phospho-p38 MAPK, anti-phospho-
MKK3/6 and anti-phospho-Akt antibodies were purchased from
New England Biolabs (Beverly, MA, USA).
2.2. Western blot analysis
After stimulation, cells were washed with cold phosphate-bu¡ered
saline, scraped and resuspended in lysis bu¡er containing 1% Nonidet
P-40, 50 mM HEPES (pH 7.5), 100 mM NaCl, 2 mM EDTA, 1 mM
pyrophosphate, 10 mM sodium orthovanadate, 3 mM benzamidine,
1 mM phenylmethylsulfonyl £uoride and 100 mM sodium £uoride.
Cell lysates were centrifuged at 15 000 rpm for 10 min at 4‡C. The
supernatants were electrophoresed through 10% SDS^PAGE. Proteins
were transferred to nitrocellucose membrane (Bio-Rad, Richmond,
CA, USA). The blots were blocked in Tris-bu¡ered saline/Tween 20
supplemented with 5% bovine serum albumin for 1 h, incubated with
various primary Abs for 1 h and then with 1:5000 diluted secondary
Abs of horseradish peroxidase-conjugated anti-rabbit IgG or anti-
mouse IgG (Santa Cruz, CA, USA) for 1 h at room temperature.
The blots were treated with enhanced chemiluminescence reagents
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) and detected
by autoradiography.
2.3. In vitro JNK kinase assay
GST-c-Jun-(1^79) fusion protein was puri¢ed from bacterial lysates
using glutathione-S-transferase (GST)^Sepharose beads (Amersham
Pharmacia Biotech). After stimulation, HK cells were lysed in the
lysis bu¡er described in the previous section. The lysates were mixed
with 20 Wl of GST-c-Jun bound to GST^Sepharose beads. The mix-
ture was rotated at 4‡C for 1 h and pelleted by centrifugation. The
pelleted beads were washed twice with the lysis bu¡er and once with
kinase bu¡er (20 mM HEPES, pH 7.6, 20 mM MgCl2, 20 mM
L-glycerol phosphate, 0.2 mM sodium orthovanadate, 10 mM sodium
£uoride, and 0.2 mM dithiothreitol) and then resuspended in 50 Wl of
kinase bu¡er containing 50 WM ATP and 10 WCi of [Q-32P]ATP (3000
Ci/mmol, Amersham Pharmacia Biotech). After 30 min of incubation
at 30‡C, the reaction was terminated by adding 2U Laemmli sample
bu¡er and boiling for 3 min. Samples were resolved on 12% SDS^
PAGE gel and subjected to autoradiography.
2.4. Measurement of apoptosis (nuclear staining with Hoechst 33258)
HK cells plated in 12-well plates were untreated or pretreated with
20 ng/ml of IL-4 for 15 min prior to anisomycin treatment. Cells given
death-inducing stimuli were then ¢xed with 4% paraformaldehyde for
20 min at room temperature and stained with 50 ng/ml Hoechst 33258
(Sigma). For quantitation of apoptosis (presented as averageQ stan-
dard error of the mean [S.E.M.]), cells were scored as apoptotic based
on morphological criteria. A minimum of 250 cells was counted for
each condition.
2.5. Adenoviral infection
Adenovirus expressing L-galactosidase and HA-tagged constitu-
tively active myristylated Akt (myr-Akt) were kindly provided by
Dr. Walsh (Tufts University, MA, USA) [17]. HK cells were infected
with adenovirus with multiplicity of infection of 100 for 24 h, the
condition in which uniform expression of the transgenes was observed
in nearly 90% of the cells, as determined by staining the cells for
L-galactosidase activity following infection with L-galactosidase virus.
The virus was removed and cells were left to recover for 12 h in
complete medium.
3. Results
3.1. IL-4 activates ERK1/2 and PI3K/Akt pathways in
HK cells
Since IL-4 has a growth-promoting e¡ect on hematopoietic
cells, including B cells, T cells and mast cells [4,18], we exam-
ined whether this cytokine elicits such function in HK cells.
Cells maintained in 10% FCS-containing medium were stimu-
lated with various doses of IL-4 for 24 h. The e¡ect of IL-4 on
the proliferation of HK cells was measured by [3H]thymidine
incorporation during the last 16 h chasing period. Fig. 1A
shows that IL-4 increased the [3H]thymidine uptake dose-de-
pendently, suggesting that IL-4 is a growth factor for this cell
line. We next examined whether IL-4 activates ERK1/2, a
molecular hallmark of proliferation of cells. Cells that were
serum-starved by maintaining them in 0.25% FCS-containing
medium for 24 h were stimulated with IL-4 for the indicated
time and the IL-4-induced activation of ERK1/2 was deter-
mined by Western blot analysis using antibody detecting
phosphorylated ERK. Fig. 1B shows that ERK1/2 activation
by IL-4 was evident after 15 min stimulation. The level of
phosphorylation was sustained until 60 min and then de-
creased at 120 min after IL-4 treatment. This IL-4-induced
ERK1/2 activation is MEK-1 and -2 dependent, because cells
pretreated with 50 WM PD098059, an activation inhibitor of
ERK1/2, 2 h prior to stimulation did not show ERK1/2 acti-
vation upon treatment with IL-4. Experiments examining
Fig. 1. IL-4 stimulates HK cell proliferation and activates ERK1/2
and PI3K/Akt. A: HK cells were seeded in a 96-well plate at about
5000 cells/well. After 24 h incubation, the cells were treated with
IL-4 at indicated concentrations. The cells were pulsed with 0.5 WCi
of [3H]thymidine during the last 16-h period, and harvested onto ¢l-
ter. The incorporated [3H]thymidine in DNA was measured by liq-
uid scintillation counter. B: Con£uent HK cells maintained in low
serum-containing medium (0.25% FCS) for 24 h were stimulated
with IL-4 (20 ng/ml) for the indicated times. For inhibition of
ERK1/2 activation, HK cells were pretreated with 50 WM PD098059
for 2 h and subsequently stimulated with IL-4 for 15 min. Cell ly-
sates were immunoblotted using the anti-phospho-ERK antibody.
C: Serum-starved HK cell cultures were stimulated with IL-4 for
the indicated times. For inhibition of Akt activation, HK cells were
pretreated with 10 WM LY294002 (LY) or 100 nM wortmannin
(Wt) for 2 h and subsequently stimulated with IL-4 for 15 min. Akt
activation was examined by immunoblotting cell lysates with anti-
bodies to phospho-Akt or Akt.
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whether IL-4 activates other members of the MAPK family,
JNK and p38, revealed no activation of such MAPKs (data
not shown).
In addition to activating the ERK1/2 pathway, IL-4 is
shown to activate the PI3K/Akt pathway that promotes cell
survival in various cell types [19^23]. Thus, we investigated
whether Akt is activated in response to IL-4 in HK cells. As
shown in Fig. 1C, phosphorylation of Akt occurred 5 min
after cells were exposed to IL-4, reached a maximum at 30
min and gradually decreased to the basal level by 120 min.
Akt is an established downstream target of PI3K that is acti-
vated following the stimulation of cells with growth factors.
Upon treatment of HK cells with inhibitors of PI3K
(LY294002 or wortmannin) prior to IL-4 addition, the phos-
phorylation of Akt was blocked, con¢rming that IL-4-induced
Akt activation is mediated through the PI3K pathway. TNF
and sCD40L were shown not to activate Akt in this cell type
(data not shown).
3.2. IL-4 does not play a role in the protection of HK cells from
apoptosis induced by anisomycin
Considerable attention has been focused on the role of the
PI3K/Akt pathway as a source of anti-apoptotic signal. Be-
fore investigating whether IL-4-activated Akt plays a protec-
tive role in apoptosis, we initially determined what stimuli can
induce HK cell death. Among the death-inducing stimuli that
were tested, treatment of HK cells with 1 Wg/ml of anisomy-
cin, a ribotoxic drug that inhibits cellular protein synthesis,
was most e¡ective in inducing apoptosis, causing 25.5% of
cells to undergo apoptosis (Fig. 2). Anisomycin is a strong
activator of stress-induced MAPKs, p38 and JNK [15,16,
24,25]. Blockage of p38 activation by pretreating cells with a
speci¢c p38 inhibitor SB203580 caused the complete inhibition
of anisomycin-induced apoptosis, indicating that apoptosis by
anisomycin is p38-dependent. In this death-inducing system,
IL-4 pretreatment slightly augmented the apoptotic process,
leading to 29% of apoptosis in cells pretreated with IL-4 for
15 min. Activation of PI3K/Akt has been shown to inhibit
apoptosis induced by treatment of anisomycin in other cell
types [15,16] ; however, in HK cells IL-4-activated PI3K/Akt
did not exhibit such protective function.
3.3. IL-4 pretreatment augments anisomycin-induced p38
activation, which is inhibited by the blockage of
the PI3K/Akt pathway
To understand the mechanism by which IL-4 pretreatment
promotes the anisomycin-induced apoptotic process, we ex-
amined the e¡ects of IL-4-activated signals on anisomycin-
induced p38 activation because this stress-induced kinase is
involved in the induction of the apoptotic process in a variety
of cell types [15,16,24,25] as well as in HK cells. Investigation
of the activation pattern of p38 in response to anisomycin
treatment for various lengths of time revealed that HK cells
exhibited a sustained biphasic activation of p38 (Fig. 3A). 15
min exposure to IL-4 prior to treatment of anisomycin with a
suboptimal dose (0.1 Wg/ml) or with a death-inducing dose
(1 Wg/ml) for 30 min resulted in more than four-fold increase
in anisomycin-induced p38 phosphorylation as compared with
that of IL-4 unprimed cells (Fig. 3B). Somewhat unexpect-
Fig. 2. IL-4 e¡ect on anisomycin-induced HK cell apoptosis. Un-
primed HK cells or cells exposed to 20 ng/ml IL-4 for 15 min were
treated with 1 Wg/ml anisomycin (Anis) for 24 h. For inhibition of
p38 activation, HK cells were pretreated with 10 WM SB203580
(SB) for 2 h. Cells were ¢xed, stained with Hoechst dye and
counted for apoptosis. The data presented are the results of ¢ve in-
dependent experiments. The mean and S.E.M. are presented with an
asterisk where increase in percentage of apoptosis is statistically sig-
ni¢cant (P6 0.05), when compared to Anis alone.
Fig. 3. A: Persistent p38 activation by anisomycin. Serum-starved
HK cell cultures were stimulated with IL-4 (20 ng/ml) for the indi-
cated times. p38 activation was examined by immunoblotting cell ly-
sates with antibodies to phospho-p38 or p38. B,C: IL-4 pretreat-
ment augments p38 activation by anisomycin (panel B), but not
that by TNF (panel C). HK cells either unexposed or exposed to
IL-4 for 15 min were stimulated with a suboptimal dose (0.1 Wg/ml)
[Anis(0.1)] or a death-inducing dose (1 Wg/ml) of anisomycin,
[Anis(1)] or with TNF (20 ng/ml) for 30 min. For inhibition of Akt
activation, 10 WM LY294002 (LY) was treated for 2 h prior to the
indicated stimuli. Cell lysates were subjected to immunoblot analysis
for p38 activation. Quanti¢cation of bands was performed by densi-
tometry and the signal intensity of phosphorylated p38 in each lane
was normalized to the cprresponding p38 band in that lane prior to
calculation of fold increases. The same lysates were also incubated
with GST-c-Jun fusion protein, and JNK activity was measured by
the phosphorylation of c-Jun.
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edly, we repeatedly observed that this IL-4-induced enhance-
ment of p38 activation by anisomycin was attenuated when
the PI3K/Akt pathway was blocked by treatment of cells with
LY294002 before consecutive addition of IL-4 and anisomy-
cin, suggesting that IL-4-activated PI3K/Akt is involved in the
up-regulation of anisomycin-induced p38 activation. This IL-4
e¡ect appeared to be speci¢c for p38 activation, because no
signi¢cant change was seen in c-Jun phosphorylating activity
of JNK induced by anisomycin (Fig. 3B, bottom panel). Fur-
thermore, TNF-induced p38 activation was not a¡ected by
IL-4 pretreatment (Fig. 3C), suggesting a selective IL-4 e¡ect
on the regulation of anisomycin-elicited p38 activation.
3.4. Akt up-regulates anisomycin-induced p38 activation
pathway
To seek further evidence that the increased anisomycin-in-
duced p38 phosphorylation by IL-4 is mediated by Akt acti-
vation, recombinant adenovirus-mediated gene transfer meth-
od was employed to facilitate ectopic expression of Akt
proteins in HK cells. Fig. 4A shows that infection of HK cells
with a constitutively active form of Akt (myr-Akt, HA-
tagged) increased the anisomycin-induced phosphorylation
of p38 9.2-fold compared to control cells infected with L-ga-
lactosidase adenovirus which showed 4.3-fold increase. How-
ever, TNF-induced p38 phosphorylation was not signi¢cantly
a¡ected by expression of the myr-Akt. These data con¢rm the
results shown in Section 3.3, demonstrating that IL-4-acti-
vated Akt is responsible for the sensitization of the anisomy-
cin-triggered p38 signaling pathway.
To examine whether Akt can up-regulate p38 upstream ac-
tivators MKK3/6, HK cells infected with adenovirus express-
ing the L-galactosidase or myr-Akt were treated with aniso-
mycin for various time periods and processed for immunoblot
analysis using the phosphotyrosine-speci¢c MKK3/6 antibody
(Fig. 4B). Compared to cells infected with control L-galacto-
sidase adenovirus, cells infected with the myr-Akt adenovirus
showed stronger band intensities of phosphorylated MKK3/6
by anisomycin treatment. The increase in the phosphorylation
of MKK3/6 paralleled the phosphorylation of p38 for the
time periods examined. Infection with the myr-Akt virus itself
phosphorylated MKK3/6 (the second lane in the panel
marked by P-MKK3/6). These results indicate that Akt
cross-talks with the p38 signaling pathway at the level or up-
stream of MKK3/6 in HK cells.
4. Discussion
In the present study, we report that an established FDC line
of HK cells responded to IL-4 by activating ERK1/2 and
PI3K/Akt pathways. Akt activated by IL-4 did not contribute
to the prevention of anisomycin-induced HK cell death, it
rather facilitated the apoptotic process by up-regulating the
p38 signaling pathway. IL-4 alone did not induce the activa-
tion of p38 in this cell line, but it assisted the anisomycin-
elicited p38 activation through Akt activation, suggesting a
positive cross-talk between the p38 MAPK and PI3K/Akt
pathways.
Activation of PI3K/Akt functions as a source of survival
and anti-apoptotic signals, and often cross-talks with the p38
signaling pathway. Berra et al. [26] have shown that simple
inhibition of ERK activation by PD098059 in HeLa cells cul-
tured in serum-free medium causes sustained p38 activation,
leading to apoptosis induction. This e¡ect can be blocked by
the presence of serum through the PI3K/Akt signaling path-
way, suggesting that PI3K/Akt signaling antagonizes p38 ac-
tivation and subsequent apoptosis induction. Similarly, in en-
dothelial cells, vascular endothelial growth factor activates the
PI3K/Akt pathway to protect cells from apoptosis by down-
regulating the p38 signaling pathway [27]. However, in other
instances PI3K/Akt up-regulates the activation of p38. Ac-
cording to the work done by Madrid et al. [28], in the context
of IL-1L-induced Akt activation, treatment of cells with IL-1L
or expression of myr-Akt enhanced the phosphorylation and
activation of p38, and this increased p38 activity was shown
to increase the transcriptional potential of NF-UB. Further-
more, it has been demonstrated that Akt forms a stable com-
plex with p38 in human neutrophils [29]. Therefore, it is likely
that the PI3K/Akt pathway regulates the activation of p38 in
a positive or negative manner. Since activation of p38 appears
to be critically associated with the anisomycin-induced HK
cell death (Fig. 2), the slight death-promoting e¡ect on aniso-
mycin-induced cell death in HK cells appears to be mediated
Fig. 4. Akt up-regulates the activation of p38 signaling by anisomycin. A: HK cells were infected with adenoviruses for L-galactosidase (Ad
L-Gal) and HA-tagged myr-Akt (Ad myr-Akt). After 24 h incubation in complete medium, cells were serum-starved and treated with TNF (20
ng/ml) or anisomycin (1 Wg/ml) for 30 min. Cell lysates were subjected to immunoblot analysis with antibodies speci¢c to phospho-p38, p38, or
HA. A representative result of three independent experiments is shown. Intensity of phospho-p38 bands in each lane was quanti¢ed by scanning
densitometry of immunoblot. Fold increases in the phospho-p38 levels were calculated after normalizing the levels to p38 levels in each lane.
B: HK cells were infected with adenoviruses as indicated. Cells were serum-starved and stimulated with anisomycin for the times indicated.
Cell lysates were processed for immunoblot analysis with antibodies to phospho-p38, phospho-MKK3/6, HA, or L-actin.
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by the up-regulation of p38 activity by Akt that is activated
by IL-4.
Positive regulation of the p38 pathway by Akt in HK cells
involves the utilization of the p38-activating kinase MKK3/6,
as shown by the fact that over-expression of activated Akt
alone can induce the phosphorylation of MKK3/6, and in-
creases the anisomycin-induced MKK3/6 phosphorylation
(Fig. 4). In addition, it has been suggested that down-regula-
tion of p38 signaling by Akt also involves the modulation of
MKK3/6 activity by phosphorylating MKK upstream kinase
MEKK3 in endothelial cells, whose phosphorylation reduces
its activity to activate the MKK3/6^p38 pathway [27]. How
Akt activates the MKK3/6^p38 pathway in HK cells is pres-
ently unclear, but we showed that IL-4-activated Akt in-
creased p38 phosphorylation by anisomycin, but not that by
TNF. Since MKK3/6 are also critical components of the
TNF-stimulated p38 signaling pathway [30] and shown to
be phosphorylated by TNF treatment in HK cells (data not
shown), positive cross-talk between IL-4-induced Akt and ani-
somycin-induced p38 signaling pathways must occur upstream
of MKK3/6. Recently it has been demonstrated that anisomy-
cin-stimulated signaling to p38 activation originates further
upstream of MKK family enzymes and utilizes components
which are not involved in TNF receptor-mediated kinase ac-
tivation [25]. Further studies will be required to identify the
molecular basis of this cross-talk event.
Although activation of the PI3K/Akt pathway is required
and su⁄cient for cell survival, this does not seem to be always
the case. For example, inhibition of the PI3K/Akt pathway
does not induce apoptosis in cerebellar granule neurons main-
tained in serum and potassium-rich medium [31], and in supe-
rior cervical neurons [32]. Furthermore, a recent study has
indicated that activation of Akt is pro-apoptotic under certain
circumstances [33]. It showed that when caveolin-1, the main
structural component of caveolae that modulates the activities
of molecules involved in growth factor signaling, was over-
expressed in 293 and HeLa cells, there was a signi¢cant acti-
vation of the PI3K/Akt pathway and the resulting elevated
activity of Akt sensitized cells to the stress-induced apoptosis.
Although a precise causal e¡ect of IL-4-activated Akt on the
enhanced anisomycin-induced p38 signaling and apoptosis of
HK cells has to be determined, our present study provides
additional evidence that elevated Akt activity may promote
cell death through the up-regulation of the p38 signaling path-
way.
So far, studies published to date do not point out when and
why FDCs in vivo undergo apoptosis. However, evaluation of
the FDC network for a long period of time after induction of
GC responses reveals that the FDC networks degenerate in
the resolution stage of GC [34]. Whether the major population
of FDC in the involuting follicles of normal lymphoid tissues
undergoes programmed cell death is an open question. The
fate of FDCs in vivo may be the result of a complex interplay
between signals that are delivered by GC cytokines which
include IL-4.
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